Trials / Terminated
TerminatedNCT04377620
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 211 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo administered BID approximately 12 hours apart |
| DRUG | Ruxolitinib | Ruxolitinb administered BID approximately 12 hours apart |
Timeline
- Start date
- 2020-05-24
- Primary completion
- 2021-02-26
- Completion
- 2021-02-26
- First posted
- 2020-05-06
- Last updated
- 2022-01-19
- Results posted
- 2022-01-19
Locations
36 sites across 2 countries: United States, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04377620. Inclusion in this directory is not an endorsement.